Select publications

Cassidy J et al. Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13(4):566-75. Abstract

Grothey A et al. Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): Updated results of a randomized phase II trial. Eur J Cancer Suppl 2003;1(5 Suppl):90..

Grothey A et al. Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc ASCO 2003;Abstract 1022.

Hurwitz H et al. Bevacizumab in combination with 5-fluorouracil and leucovorin: A promising regimen for first-line metastatic colorectal cancer. ASCO Gastrointestinal Cancers Symposium 2004;Abstract 286.

Hurwitz H et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc ASCO 2003;Abstract 3646.

Miller KD et al. Phase III trial of capecitabine (Xeloda®) plus bevacizumab (Avastin TM) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 2002;76(Suppl 1);Abstract 36.

Scheithauer W et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003;21(7):1307-12. Abstract

Scheithauer W et al; X-ACT Study Group. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 2003;14(12):1735-43. Abstract

Van Cutsem E et al. Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19(21):4097-106. Abstract